Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 19.47 Billion KRW | 30.42% |
| 2022 | 14.93 Billion KRW | -3.77% |
| 2021 | 15.51 Billion KRW | -23.48% |
| 2020 | 20.28 Billion KRW | -12.89% |
| 2019 | 23.28 Billion KRW | 34.12% |
| 2018 | 17.35 Billion KRW | 6.29% |
| 2017 | 16.33 Billion KRW | 9.85% |
| 2016 | 14.86 Billion KRW | 35.61% |
| 2015 | 10.96 Billion KRW | -14.25% |
| 2014 | 12.78 Billion KRW | 0.78% |
| 2013 | 12.68 Billion KRW | 8.98% |
| 2012 | 11.64 Billion KRW | 4.16% |
| 2011 | 11.17 Billion KRW | 5.89% |
| 2010 | 10.55 Billion KRW | -12.64% |
| 2009 | 12.08 Billion KRW | 17.01% |
| 2008 | 10.32 Billion KRW | 1.49% |
| 2007 | 10.17 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 21.06 Billion KRW | 5.19% |
| 2024 Q1 | 20.02 Billion KRW | 2.79% |
| 2023 Q4 | 19.47 Billion KRW | 2.08% |
| 2023 Q3 | 19.07 Billion KRW | 8.2% |
| 2023 FY | 19.47 Billion KRW | 30.42% |
| 2023 Q2 | 17.63 Billion KRW | 9.15% |
| 2023 Q1 | 16.15 Billion KRW | 8.18% |
| 2022 Q2 | 15.87 Billion KRW | 5.45% |
| 2022 Q1 | 15.05 Billion KRW | -2.99% |
| 2022 FY | 14.93 Billion KRW | -3.77% |
| 2022 Q4 | 14.93 Billion KRW | -4.8% |
| 2022 Q3 | 15.68 Billion KRW | -1.19% |
| 2021 Q1 | 18.97 Billion KRW | -6.43% |
| 2021 Q3 | 17.36 Billion KRW | -0.42% |
| 2021 Q4 | 15.51 Billion KRW | -10.63% |
| 2021 FY | 15.51 Billion KRW | -23.48% |
| 2021 Q2 | 17.43 Billion KRW | -8.12% |
| 2020 Q1 | 21.95 Billion KRW | -5.7% |
| 2020 FY | 20.28 Billion KRW | -12.89% |
| 2020 Q2 | 20.87 Billion KRW | -4.92% |
| 2020 Q4 | 20.28 Billion KRW | 0.05% |
| 2020 Q3 | 20.27 Billion KRW | -2.89% |
| 2019 Q2 | 20.65 Billion KRW | 6.67% |
| 2019 Q3 | 23.75 Billion KRW | 15.0% |
| 2019 Q4 | 23.28 Billion KRW | -1.97% |
| 2019 FY | 23.28 Billion KRW | 34.12% |
| 2019 Q1 | 19.36 Billion KRW | 11.53% |
| 2018 Q4 | 17.35 Billion KRW | -2.9% |
| 2018 Q1 | 17.42 Billion KRW | 6.7% |
| 2018 FY | 17.35 Billion KRW | 6.29% |
| 2018 Q2 | 17.22 Billion KRW | -1.16% |
| 2018 Q3 | 17.87 Billion KRW | 3.8% |
| 2017 Q2 | 14.7 Billion KRW | 1.91% |
| 2017 Q4 | 16.33 Billion KRW | 6.94% |
| 2017 FY | 16.33 Billion KRW | 9.85% |
| 2017 Q3 | 15.27 Billion KRW | 3.84% |
| 2017 Q1 | 14.43 Billion KRW | -2.93% |
| 2016 Q3 | 14.18 Billion KRW | 9.11% |
| 2016 Q4 | 14.86 Billion KRW | 4.82% |
| 2016 Q1 | 11.9 Billion KRW | 8.61% |
| 2016 FY | 14.86 Billion KRW | 35.61% |
| 2016 Q2 | 13 Billion KRW | 9.17% |
| 2015 Q1 | 12.49 Billion KRW | -2.25% |
| 2015 Q4 | 10.96 Billion KRW | -0.82% |
| 2015 Q3 | 11.05 Billion KRW | -7.65% |
| 2015 FY | 10.96 Billion KRW | -14.25% |
| 2015 Q2 | 11.96 Billion KRW | -4.22% |
| 2014 Q2 | 12.82 Billion KRW | 3.47% |
| 2014 FY | 12.78 Billion KRW | 0.78% |
| 2014 Q4 | 12.78 Billion KRW | -7.02% |
| 2014 Q3 | 13.75 Billion KRW | 7.19% |
| 2014 Q1 | 12.39 Billion KRW | -2.28% |
| 2013 Q3 | 13.54 Billion KRW | 9.32% |
| 2013 Q4 | 12.68 Billion KRW | -6.31% |
| 2013 FY | 12.68 Billion KRW | 8.98% |
| 2013 Q2 | 12.38 Billion KRW | 7.82% |
| 2013 Q1 | 11.48 Billion KRW | -1.31% |
| 2012 Q1 | 11.9 Billion KRW | 0.0% |
| 2012 FY | 11.64 Billion KRW | 4.16% |
| 2012 Q4 | 11.64 Billion KRW | -10.54% |
| 2012 Q3 | 13.01 Billion KRW | 6.56% |
| 2012 Q2 | 12.21 Billion KRW | 2.59% |
| 2011 FY | 11.17 Billion KRW | 5.89% |
| 2011 Q3 | 9.94 Billion KRW | -13.4% |
| 2011 Q2 | 11.47 Billion KRW | 10.15% |
| 2011 Q1 | 10.42 Billion KRW | -1.26% |
| 2010 Q1 | 12.08 Billion KRW | 0.03% |
| 2010 FY | 10.55 Billion KRW | -12.64% |
| 2010 Q4 | 10.55 Billion KRW | -19.54% |
| 2010 Q3 | 13.11 Billion KRW | 10.54% |
| 2010 Q2 | 11.86 Billion KRW | -1.81% |
| 2009 Q4 | 12.08 Billion KRW | 8.59% |
| 2009 FY | 12.08 Billion KRW | 17.01% |
| 2009 Q2 | 11.82 Billion KRW | 6.62% |
| 2009 Q1 | 11.09 Billion KRW | 7.44% |
| 2009 Q3 | 11.12 Billion KRW | -5.94% |
| 2008 Q1 | 8.66 Billion KRW | -14.84% |
| 2008 Q3 | 8.52 Billion KRW | 14.7% |
| 2008 FY | 10.32 Billion KRW | 1.49% |
| 2008 Q4 | 10.32 Billion KRW | 21.12% |
| 2008 Q2 | 7.43 Billion KRW | -14.22% |
| 2007 Q1 | 10.4 Billion KRW | 0.0% |
| 2007 Q3 | 10 Billion KRW | -2.45% |
| 2007 Q2 | 10.26 Billion KRW | -1.35% |
| 2007 FY | 10.17 Billion KRW | 0.0% |
| 2007 Q4 | 10.17 Billion KRW | 1.63% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 55.887% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 83.473% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 78.636% |
| HANDOK Inc. | 94.46 Billion KRW | 79.382% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | 8.313% |
| Yuhan Corporation | 284.75 Billion KRW | 93.16% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 83.255% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -19.795% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 93.256% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 39.856% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 68.445% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | 35.677% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 59.714% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 55.887% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 37.655% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 44.63% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 59.531% |
| JW Holdings Corporation | 147.58 Billion KRW | 86.803% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 76.984% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 92.55% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 81.641% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 63.88% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | 27.857% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 40.092% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 82.256% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 55.887% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 89.675% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 91.936% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 81.641% |
| Yuhan Corporation | 284.75 Billion KRW | 93.16% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 84.453% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 68.579% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 92.504% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 81.641% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 75.532% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 60.366% |
| CKD Bio Corp. | 69.08 Billion KRW | 71.806% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 81.464% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 72.45% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 63.97% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 63.88% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 90.0% |
| Boryung Corporation | 189.8 Billion KRW | 89.738% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 65.729% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 68.445% |
| JW Lifescience Corporation | 23.39 Billion KRW | 16.76% |